NewTimeSpace News: IMMUNEONCO-B (01541.HK): The Company's non-wholly-owned subsidiary Yiming Kaier received a capital increase of RMB 50 million in total consideration from investors including Shengke Qihang, Xinjie Chuangyuan and Mr. Wang Xueyan, with the investors subscribing for approximately 15.83% of the enlarged equity; upon completion the Company will hold approximately 68.34%, the target company will remain a non-wholly-owned subsidiary, and the transaction is fully exempt from Chapter 14 of the Listing Rules.
NewTimeSpace News: CHK OIL (00632.HK): Mr. Zheng Zhensheng has resigned as CFO, company secretary, authorised representative and process agent with effect from 7 August 2026; following the resignation the Company is temporarily not in compliance with Rules 3.05, 3.28 and 19.05(2) of the Listing Rules relating to authorised representatives, company secretary and process agent, and is seeking candidates to fill the vacancies as soon as practicable.
NewTimeSpace News: TONTINE WINES (00389.HK): The Company received notice of court proceedings commenced by Shuntuo Development Limited and Mr. Wang He in the High Court of Hong Kong (Miscellaneous Proceedings No. 1316 of 2026) over the placing agreement, seeking declarations that the agreement is void and injunctions; the Company intends to actively defend, and the Board considers the proceedings have no immediate material adverse impact on the Group's existing business operations or financial position.
NewTimeSpace News: TRANSCENTA-B (06628.HK): The Company's wholly-owned subsidiary proposes to dispose of its CDMO assets to a wholly-owned subsidiary of WuXi Biologics for RMB 190 million, with an estimated loss of approximately RMB 280 million to be recognised; the transaction constitutes a major transaction subject to shareholders' approval, with the circular expected to be despatched on or before 25 August 2026.
NewTimeSpace News: OCT (ASIA) (03366.HK): The Company proposes to dispose of the 100% equity interest in OCT (Huizhou) Industrial Park Management Co., Ltd. through a public listing for a final consideration of RMB 306,732,900, with Shenghong Technology (Huizhou) Co., Ltd. as the purchaser; the target property was valued at approximately RMB 280 million, representing an appreciation of approximately RMB 154 million over book value; an EGM will be held on 21 August 2026.
CCTC(06951.HK) will spend CNY 159.56 million to repurchase 1.29 million shares on Aug 6, 2026 .
NewTimeSpace News: DRAGON MINING announced that its wholly-owned subsidiary Lung Kam Resources will list on the HKEX Main Board by way of introduction, with each scheme share exchanged for one New Holding Company share and the Company's listing withdrawn upon completion; dealings in the New Holding Company shares are expected to commence on 2 September 2026 under the existing code 1712 with the short name "Dragon Mining" and a board lot of 1,000 shares; the scheme remains subject to court approval.
NewTimeSpace News: TRANSTHERA-B announced that its self-developed Class 1 new drug Jientai (tiengotinib tablets) has received conditional NMPA approval for marketing, for advanced cholangiocarcinoma with FGFR2 fusions or rearrangements in patients previously treated with systemic therapy and FGFR inhibitors; the Phase II pivotal study showed an ORR of 28.0% and median overall survival of 20.7 months; the drug has received US FDA Orphan Drug Designation and Fast Track Designation and European EMA Orphan Drug Designation, and this is its first indication approved in China.
NewTimeSpace News: TOP EDUCATION announced that on 5 August it became aware of a threat actor claiming to possess and intend to sell records allegedly relating to students on an underground forum; the Group has immediately launched an investigation and notified the Tertiary Education Quality and Standards Agency and the Australian Cyber Security Centre; the suspected incident has not caused material disruption to the Group's operations to date, and the Group will take appropriate actions as the investigation progresses.
NewTimeSpace News: HENGRUI PHARMA announced that the third indication of its subsidiary Suzhou Shengdiya's trastuzumab rezetecan for injection has been approved for marketing, for adult patients with HER2-positive colorectal cancer who failed oxaliplatin, fluorouracil and irinotecan, making it the first anti-HER2 product approved for colorectal cancer in China; the self-developed HER2 ADC has its pivotal Phase III data presented at the 2026 ASCO Annual Meeting, 11 indications included in the Breakthrough Therapy Designation list, and cumulative R&D investment of approximately RMB 2.144 billion.
NewTimeSpace News: HENGRUI PHARMA announced that the NMPA has approved a fifth indication for its self-developed Class 1 innovative drug ivarmacitinib sulfate tablets, for adult patients with active non-radiographic axial spondyloarthritis, achieving full-disease-spectrum oral targeted management coverage of axial spondyloarthritis; the product is a highly selective JAK1 inhibitor with pivotal Phase III data presented at the 2026 EULAR Annual Meeting, and cumulative R&D investment of approximately RMB 1.235 billion.
NewTimeSpace News: ENVISION GREEN announced that its indirect wholly-owned subsidiary Shanghai Youfu Cloud Computing intends to purchase high-performance servers for RMB 1.2884 billion (approximately HKD 1.4885 billion, inclusive of tax) from Shanghai Shunquan Technology to support the Group's cloud computing and intelligent computing capabilities; as the applicable percentage ratios exceed 25% but are below 100%, the transaction constitutes a major transaction; written approval from shareholders holding approximately 50.62% has been obtained, and no general meeting will be convened.
NewTimeSpace News: NETJOY announced that its independent internal control follow-up review has been completed; all remedial measures recommended in the internal control review report have been implemented and are operating, except for procurement acceptance processes (not applicable as the Group ended its new short-drama purchase business in June) and inventory transfers (no samples available as the Group operates a single warehouse), with the Board affirming the rectification results; the Company's shares have been suspended since 1 April 2025 and will remain suspended until all resumption guidance is met.
NewTimeSpace News: August 06, 2026, PACIFIC BASIN(02343.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 1.11 billion, increased by 8.52% YoY.
NewTimeSpace News: August 06, 2026, TOM GROUP(02383.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 335.25 million, decreased by 1.02% YoY.
NewTimeSpace News: CITIC SEC announced the completion of the issue of 803,725,383 new H shares to CITIC Financial Holdings on 6 August 2026 at an issue price of HKD 23.13 per share, with total proceeds of RMB 16 billion and net proceeds of approximately HKD 18.413 billion; following completion, CITIC Financial Holdings holds approximately 23.96% of the Company, with the new H shares subject to a 48-month lock-up; all net proceeds will be retained overseas for international business development, including capital injection of up to RMB 16 billion into CITIC Securities International.
